Heart International最新文献_第6页

Endoleak after Endovascular Abdominal Aortic Aneurysm Repair Treated by Bilateral Transradial Access: Case Report. 双侧经桡动脉通路治疗腹主动脉瘤腔内修复术后腔内渗漏1例。

IF 0.2

Heart International Pub Date : 2021-12-20 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.106

Gustavo A Samaja, Heber Tejerina Segovia, José M Escalante, Corina Biagioni, Silvana Onorato Grats

引用次数: 0

Coronary Revascularization and Out-of-hospital Cardiac Arrest: Past, Present and Future. 冠状动脉血管重建与院外心脏骤停：过去、现在和未来。

IF 0.2

Heart International Pub Date : 2021-12-20 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.94

Matthew E Li Kam Wa, Kalpa De Silva, Nilesh Pareek, Divaka Perera

{"title":"Coronary Revascularization and Out-of-hospital Cardiac Arrest: Past, Present and Future.","authors":"Matthew E Li Kam Wa, Kalpa De Silva, Nilesh Pareek, Divaka Perera","doi":"10.17925/HI.2021.15.2.94","DOIUrl":"10.17925/HI.2021.15.2.94","url":null,"abstract":"Cardiologists and the cardiac catheter laboratory have key roles to play in the management of patients after out-of-hospital cardiac arrest (OHCA). Although immediate catheter laboratory activation is the standard of care in cardiogenic shock and ST elevation myocardial infarction, the majority of patients will present without these features and with an uncertain diagnosis. Even in the latter, early assessment and invasive management may be beneficial, but this is counterbalanced by significant resource utilization, potential to cause harm and the possibility that any diagnostic or therapeutic gains are offset by a poor neurological outcome. Past consensus on the management of the OHCA patient without ST elevation or cardiogenic shock is being challenged by emerging results from new trials in this field. Further randomized trials are ongoing, and are expected to deliver robust data from over 4,000 patients, allowing us to further refine the optimal management strategy in this challenging cohort. This article describes the benefits and pitfalls of a strategy of immediate coronary angiography in these patients, examines the recently published COACT and TOMAHAWK trials in detail, and describes a framework with which to approach the patient after resuscitated OHCA, based on the available evidence to date.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"94-102"},"PeriodicalIF":0.2,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524604/pdf/heart-int-15-94.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: 'The New Normal'? XIENCE植入后短期双重抗血小板治疗:“新常态”?

IF 0.2

Heart International Pub Date : 2021-12-10 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.65

Niels Mr van der Sangen, Wouter J Kikkert, José Ps Henriques, Bimmer Epm Claessen

引用次数: 1

An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease. 外周动脉药物洗脱技术治疗外周动脉疾病的研究进展

IF 0.2

Heart International Pub Date : 2021-12-10 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.73

Leonardo Marques, Silke Hopf-Jensen, Michael Preiss, Stefan Mueller-Huelsbeck

引用次数: 2

An Unusual Cause of Pacemaker Lead Displacement: 'Reverse Ratchet' Syndrome. 起搏器导线移位的一个特殊原因：“反向棘轮”综合征。

IF 0.2

Heart International Pub Date : 2021-11-16 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.103

Haytham Enab, Colin Cunnington, Amir Zaidi

引用次数: 1

The HEP-COVID Trial. HEP-COVID试验。

IF 0.2

Heart International Pub Date : 2021-10-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.62

Alex C Spyropoulos

引用次数: 1

Comprehensive Review of Complete Versus Culprit-only Revascularization for Multivessel Disease in ST-segment Elevation Myocardial Infarction. st段抬高型心肌梗死多血管病变的完全血管重建术与单纯罪犯血管重建术的综合评价

IF 0.2

Heart International Pub Date : 2021-08-02 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.54

Robin Jacob, Ayaaz K Sachedina, Sachin Kumar

{"title":"Comprehensive Review of Complete Versus Culprit-only Revascularization for Multivessel Disease in ST-segment Elevation Myocardial Infarction.","authors":"Robin Jacob, Ayaaz K Sachedina, Sachin Kumar","doi":"10.17925/HI.2021.15.1.54","DOIUrl":"https://doi.org/10.17925/HI.2021.15.1.54","url":null,"abstract":"Several organizations have developed guidelines for the management of ST-segment elevation myocardial infarction (STEMI). However, the optimal strategy regarding revascularization in the setting of multivessel disease, specifically with regards to culprit vessel versus complete revascularization, continues to evolve. While previous observational studies promoted culprit vessel-only intervention in patients with STEMI, recent randomized controlled trials suggest potential benefits with multivessel revascularization, either at the time of the index event or in a staged fashion, in patients without cardiogenic shock. This may be due to the known instability of non-culprit lesions in the setting of acute coronary syndrome, and the diffuse coronary processes involved. As additional literature examines culprit vessel versus multivessel revascularization strategies, clinicians continue to be tasked with determining optimal treatment plans for their patients and understanding the factors that promote selected revascularization strategies. This review summarizes and discusses observational studies, randomized control trials and current guidelines in order to evaluate optimal reperfusion strategies for patients presenting with STEMI in the setting of multivessel disease.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"54-59"},"PeriodicalIF":0.2,"publicationDate":"2021-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524594/pdf/heart-int-15-54.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40568361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. 外周动脉疾病中动脉粥样硬化血栓事件二级预防的药物治疗。

IF 0.2

Heart International Pub Date : 2021-07-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.14

Justin T Morrison, Judith Hsia, Marc P Bonaca

{"title":"Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease.","authors":"Justin T Morrison, Judith Hsia, Marc P Bonaca","doi":"10.17925/HI.2021.15.1.14","DOIUrl":"https://doi.org/10.17925/HI.2021.15.1.14","url":null,"abstract":"Patients with peripheral artery disease (PAD) are at risk for severe morbidity and mortality, including ischaemic-related events. Furthermore, there is heterogeneity within the PAD population, where the drivers of risk for cardiovascular and limb-specific ischaemic events differ. Patients with PAD with concomitant coronary artery disease are at increased risk for cardiovascular ischaemic events, whereas patients with PAD with a prior history of lower-extremity revascularization are at increased risk for limb-specific ischaemic events. The current therapeutic challenge is identifying these risk factors to tailor therapy optimally for each patient. Additionally, the majority of our current medical therapeutics in patients with PAD have been shown to reduce atherothrombotic events, such as myocardial infarction, stroke and cardiovascular death, with a paucity of medical therapeutics specifically targeting a reduction in limb-specific ischaemic events. Over the past several years, there have been several contemporary clinical trials evaluating antithrombotic agents and their efficacy in reducing limb-specific ischaemic events. Specifically, rivaroxaban, with the addition of aspirin, has emerged as an efficacious therapeutic. In this article, we provide a review of the current clinical burden of PAD, the rationale behind current PAD medical therapeutics and the contemporary trials that have described the benefit of a novel therapeutic in PAD, rivaroxaban.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"14-19"},"PeriodicalIF":0.2,"publicationDate":"2021-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524742/pdf/heart-int-15-14.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40583010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The ACURATE neo™ and neo2™ Valve Systems. accurate neo™和neo2™阀门系统

IF 0.2

Heart International Pub Date : 2021-07-16 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.37

Michael J Reardon

引用次数: 1

Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk. 高心血管风险患者的双重抗血小板疗法。

IF 1.9

Heart International Pub Date : 2021-07-16 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.26

Clifton Espinoza, Debabrata Mukherjee

{"title":"Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk.","authors":"Clifton Espinoza, Debabrata Mukherjee","doi":"10.17925/HI.2021.15.1.26","DOIUrl":"10.17925/HI.2021.15.1.26","url":null,"abstract":"Coronary artery disease (CAD) is prevalent throughout the world, with a significant impact on global health. There is a vast collection of data in the medical literature relating to the topic of dual antiplatelet therapy (DAPT) in patients considered to be at high cardiovascular (CV) risk. In order to perform a narrative review of literature regarding the use of DAPT in patients with high CV risk, PubMed, Google Scholar and Embase were searched for English-language articles from 1985 to December 2020 by using the medical subject heading terms and keywords 'antiplatelet therapy' and 'high-risk cardiovascular disease', alone or in combination. Both authors critically reviewed the design, population characteristics and results of the selected studies. The topic of DAPT in patients with high CV risk is fluid and constantly evolving. The landmark trials of CURE, TRITON-TIMI 38 and PLATO provided evidence for the optimal use of DAPT in patients after acute coronary syndrome, while the CHARISMA and MATCH trials provided guidance for clinicians for their use in patients with stable coronary artery disease. The American College of Cardiology/American Heart Association focused update, published in 2016, and the European Society of Cardiology guidelines, published in 2017, were developed to provide guidance to clinicians based on the available data at the time to be able to choose the appropriate DAPT strategy that would provide patients with the maximum clinical benefit. The management of DAPT in patients with high CV risk is a challenging task, with new data on the subject constantly being reported. Balancing ischaemic benefit with potential bleeding complications adds to the complexity of managing DAPT in these patients. With all the available data and current clinical guidelines, patients deemed at high CV risk should be considered for DAPT, taking into account individual risk:benefit ratio. In most individuals with high CV risk, the net clinical benefit favours the use of DAPT.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"26-36"},"PeriodicalIF":1.9,"publicationDate":"2021-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584145/pdf/heart-int-15-26.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40583009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0